Capricor Therapeutics, Inc. (CAPR)
8.95
+0.01
(+0.11%)
USD |
NASDAQ |
Oct 02, 16:00
9.02
+0.07
(+0.78%)
After-Hours: 20:00
Capricor Therapeutics Net Income (Quarterly) : -40.73M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -40.73M |
| March 31, 2026 | -33.94M |
| December 31, 2025 | -30.17M |
| September 30, 2025 | -24.57M |
| June 30, 2025 | -25.91M |
| March 31, 2025 | -24.39M |
| December 31, 2024 | -7.117M |
| September 30, 2024 | -12.56M |
| June 30, 2024 | -11.00M |
| March 31, 2024 | -9.794M |
| December 31, 2023 | -0.7621M |
| September 30, 2023 | -6.391M |
| June 30, 2023 | -7.367M |
| March 31, 2023 | -7.768M |
| December 31, 2022 | -7.721M |
| September 30, 2022 | -6.371M |
| June 30, 2022 | -7.109M |
| March 31, 2022 | -7.818M |
| December 31, 2021 | -6.190M |
| September 30, 2021 | -3.932M |
| June 30, 2021 | -4.748M |
| March 31, 2021 | -5.152M |
| December 31, 2020 | -4.178M |
| September 30, 2020 | -3.910M |
| June 30, 2020 | -3.484M |
| Date | Value |
|---|---|
| March 31, 2020 | -2.085M |
| December 31, 2019 | -1.469M |
| September 30, 2019 | -1.607M |
| June 30, 2019 | -2.046M |
| March 31, 2019 | -2.519M |
| December 31, 2018 | -3.260M |
| September 30, 2018 | -4.136M |
| June 30, 2018 | -4.124M |
| March 31, 2018 | -3.672M |
| December 31, 2017 | 12.31M |
| September 30, 2017 | -2.735M |
| June 30, 2017 | -3.472M |
| March 31, 2017 | -3.667M |
| December 31, 2016 | -4.518M |
| September 30, 2016 | -5.333M |
| June 30, 2016 | -4.689M |
| March 31, 2016 | -4.266M |
| December 31, 2015 | -3.346M |
| September 30, 2015 | -2.912M |
| June 30, 2015 | -3.123M |
| March 31, 2015 | -3.476M |
| December 31, 2014 | -1.928M |
| September 30, 2014 | -1.544M |
| June 30, 2014 | -1.534M |
| March 31, 2014 | -1.211M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ARS Pharmaceuticals, Inc. | -62.34M |
| SELLAS Life Sciences Group, Inc. | -9.605M |
| Sionna Therapeutics, Inc. | -29.89M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Cytokinetics, Inc. | -198.76M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 40.73M |
| EPS Diluted (Quarterly) | -0.7032 |
| Enterprise Value | 373.19M |
| Earnings Yield | -27.37% |
| Normalized Earnings Yield | -27.37 |